Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
Article Details
- CitationCopy to clipboard
Ghosh AK, Dawson ZL, Mitsuya H
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
Bioorg Med Chem. 2007 Dec 15;15(24):7576-80. Epub 2007 Sep 14.
- PubMed ID
- 17900913 [ View in PubMed]
- Abstract
Our structure-based design strategies which specifically target the HIV-1 protease backbone, resulted in a number of exceedingly potent nonpeptidyl inhibitors. One of these inhibitors, darunavir (TMC114), contains a privileged, structure-based designed high-affinity P2 ligand, 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis-THF). Darunavir has recently been approved for the treatment of HIV/AIDS patients harboring multidrug-resistant HIV-1 variants that do not respond to previously existing HAART regimens.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Darunavir Human immunodeficiency virus type 1 protease Protein Human immunodeficiency virus 1 YesInhibitorDetails